Sufentanil Sublingual Tablet (Dsuvia) — CPB 0944 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0944 covering sufentanil sublingual tablet (Dsuvia), effective December 10, 2025. The policy denies medical necessity for all acute pain indications under G89.11–G89.18 and flags all other uses as experimental. Here's what billing teams need to do.

If your facility or practice has billed — or considered billing — for Dsuvia, this update locks the door. Aetna's Dsuvia coverage policy now formally designates the drug as not medically necessary for its primary FDA-approved indication and experimental for everything else. There is no covered pathway under CPB 0944 in the Aetna system. That's a rare position for a payer to take this explicitly, and it has direct consequences for your claims and reimbursement strategy.

Quick-Reference Table

Aetna Sufentanil (Dsuvia) Coverage Criteria and Medical Necessity Requirements 2025

The short version: there are no coverage criteria that allow reimbursement for Dsuvia under Aetna commercial plans. The updated CPB 0944 Aetna policy doesn't create a threshold you need to clear — it eliminates the covered pathway entirely.

Aetna's position is explicit. The payer considers sufentanil sublingual tablet (Dsuvia) not medically necessary for the treatment of acute pain severe enough to require an opioid analgesic. That's the drug's FDA-approved indication. Aetna is saying the safety data for that specific use hasn't been established to their standard.

Medical necessity is the hinge point in most drug coverage disputes. When a payer uses the phrase "safety for this indication has not been established," they're signaling that no amount of clinical documentation will flip this denial. This isn't a documentation problem — it's a coverage problem.

For Aetna commercial plan billing, the acute pain diagnosis codes G89.11 through G89.18 are the codes most likely to appear on Dsuvia claims. Every one of those codes maps to a denied indication under this policy. If your billing team sees those codes paired with a Dsuvia claim, expect a claim denial.

Aetna Dsuvia Exclusions and Non-Covered Indications

Beyond the acute pain denial, Aetna goes further. The payer designates Dsuvia as experimental, investigational, or unproven for all other indications. This is a blanket exclusion. There is no off-label use, no clinical scenario, and no documentation strategy that currently supports coverage under this policy.

The "experimental, investigational, or unproven" designation is significant. It's a stronger statement than a simple non-covered exclusion. It tells you that Aetna has reviewed the peer-reviewed published medical literature and concluded the evidence base doesn't support the drug for anything beyond acute pain — and even for acute pain, the safety concern disqualifies it.

The real issue here is that this creates a two-layer denial structure. First, the primary FDA indication fails on medical necessity grounds. Second, any alternative indication fails on experimental grounds. Your billing team has no route around this in the Aetna commercial system.

If you're billing Dsuvia in a setting like a hospital outpatient department or ambulatory surgical center where payer mix includes Aetna commercial members, this policy should be in your denial prevention protocols before claims go out the door.

Coverage Indications at a Glance

Aetna Dsuvia Billing Guidelines and Action Items 2025

This policy is already in effect. The effective date is December 10, 2025. If you haven't acted yet, act now.

CPT, HCPCS, and ICD-10 Codes for Sufentanil Sublingual Tablet (Dsuvia) Under CPB 0944

The policy data for CPB 0944 does not list specific CPT or HCPCS procedure codes. Dsuvia is a drug administered in clinical settings, and billing typically occurs through drug billing codes your pharmacy or facility team assigns — but Aetna's policy document does not enumerate those codes in this bulletin.

What the policy does provide is the full set of ICD-10-CM diagnosis codes tied to the covered (or in this case, non-covered) indications. Use these codes to flag Dsuvia claims in your billing system.

Key ICD-10-CM Diagnosis Codes Under CPB 0944

These are the acute pain diagnosis codes addressed by this policy. All eight are mapped to the "not medically necessary" determination for Dsuvia under Aetna's current coverage policy. The descriptions below reflect exactly what CPB 0944 states.

Note: CPB 0944 lists all eight codes with the description "Acute pain" and does not provide more specific sub-descriptions. For the full clinical specificity of each G89 sub-code (e.g., acute post-thoracotomy pain, acute pain due to trauma), refer to the ICD-10-CM tabular list directly — that detail comes from the ICD-10-CM coding manual, not from this policy bulletin.

Every one of these codes maps to a denied indication under CPB 0944. If Dsuvia appears on a claim with any of these diagnosis codes billed to an Aetna commercial plan, the policy grounds for denial are clear.

Build these codes into your billing guidelines as a denial-prevention filter. When these G89 codes appear alongside sufentanil sublingual tablet billing for an Aetna commercial member, your team should catch it before submission — not after the remittance advice comes back.